Research Funded

Dissecting DNA damage and repair pathways in leiomyosarcomas: Improving therapy by understanding biology

Annette Duensing, MD, University of Pittsburgh Cancer Institute
Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Leiomyosarcomas (LMS) are aggressive tumors of the smooth muscle with no available effective treatments and a 2-year survival rate of 20%. They represent up to 25% of all soft tissue sarcomas (STS) and are the most common ... Read More

Single-cell transcriptomics and epigenomics to identify tumor-microenvironment Interactions for targeted treatment of MPNST

Lai Man Natalie Wu, PhD, Cincinnati Children’s Hospital Medical Center
Recipient of the: $50,000 Zach Cohen Memorial Research Award

Abstract: MPNST (malignant peripheral nerve sheath tumors) are highly aggressive soft tissue sarcomas of Schwann cell (SC) origin, representing a major cause of mortality in neurofibromatosis (NF) patients, which affects 1 in 3500 i... Read More

Intratumoral heterogeneity in dedifferentiated liposarcoma

Joshua Waterfall, PhD, Institut Curie (France)
Recipient of the: $50,000 Jay Vernon Jackson Memorial Research Award

Abstract: Soft tissue sarcomas are a rare entity of very heterogeneous tumors, both epidemiological, histological and molecular. Clinically, sarcomas can occur at any age of life and develop throughout the body. They are associated ... Read More

Resetting the epigenetic addiction in leiomyosarcomas: a therapeutic perspective

Claudio Brancolini, PhD, University of Udine (Italy)
Recipient of the: $50,000 Spring for Sarcoma York, PA, Sarcoma Research Award

Abstract: Leiomyosarcomas (LMS) are rare highly malignant tumors of mesenchymal origin. Standard treatment is surgery and adjuvant radiotherapy. Unfortunately, local recurrence and metastasis develop in approximately 40% of cases, w... Read More

Switching the tumor immune microenvironment from “cold” to “hot” in UPS

Jlenia Guarnerio, PhD, Cedars-Sinai Medical Center
Recipient of the: $50,000 Spring for Sarcoma York, PA, Sarcoma Research Award

Abstract: Undifferentiated Pleiomorphic Sarcoma (UPS) is one of the most aggressive subtypes of soft tissue sarcoma. Besides earlier detection by novel imaging techniques, little has been found to improve the overall survival of the... Read More

Immune profiling of pleomorphic rhabdomyosarcoma

Andrew Futreal, PhD, MD Anderson Cancer Center
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Pleomorphic rhabdomyosarcoma (PRMS) is a rare soft tissue tumor of the skeletal muscle that occurs predominantly in middle-aged adults. No standard systemic therapy options are available, and surgical resection is the most... Read More

Characterizing the Genetic Landscape of Radiation Associated Cutaneous Angiosarcomas

David Shultz, MD, PhD, Princess Margaret Cancer Centre (Canada)
Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Radiation-associated cutaneous angiosarcoma (RAA) is a highly aggressive malignancy that arises in breast cancer patients approximately 5-10 years following treatment with adjuvant radiotherapy (RT). The median survival of... Read More

Elimination of Macrophages to Improve T cell Therapy in Synovial Sarcoma

Seth Pollack, MD, Fred Hutchinson Cancer Research Center
Recipient of the: Bud Lawall Memorial Research Award

Abstract: Synovial Sarcoma is a soft tissue sarcoma subtype with poor outcomes in the advanced setting. Although it is immunologically “cold,” it generally expresses the highly immunogenic protein NY-ESO-1. Although NY-ESO-1 has... Read More

Modeling, Characterizing, and Targeting Aggressive, STAG2-mutated Ewing Sarcoma

Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center
Recipient of the: Catherine Malatesta Memorial Research Award

Abstract: Loss of function mutations of STAG2 occur in 10-15% of Ewing sarcoma (ES) patients. This is clinically significant, as loss of STAG2 is associated with poor clinical outcomes. STAG2 encodes a protein that is central to the... Read More

BMI1 as a Novel Driver and Target in Alveolar Rhabdomyosarcoma

Robert Schnepp, MD, PhD, Emory University - Winship Cancer Institute
Recipient of the: Derek G. Schnapp Memorial Research Award

Abstract: Despite significant efforts within oncology, effective therapies for alveolar rhabdomyosarcoma (ARMS) remain unrealized. Patients with ARMS are treated with intensive multimodal therapy, but outcomes still remain unaccepta... Read More

Global impact of the DNA/RNA helicase DHX9 on the processing of coding and noncoding transcripts in Ewing sarcoma pathogenesis

Maria Paola Paronetto, PhD, IRCCS Santa Lucia Foundation
Recipient of the: Pittsburgh Cure Sarcoma Research Award

Abstract: Ewing Sarcomas (ES) are biologically aggressive tumors of bone and soft tissues, characterized by in frame chromosomal translocation leading to the expression of the EWS-FLI1 oncogene. They affect mainly children and adole... Read More

Clinical Evaluation of BET and HDAC Inhibition in Canine Sarcoma

Tzipora Eisinger, PhD, University of Pennsylvania
Recipient of the: Race to Cure Sarcoma Research Award

Abstract: Targeting chromatin-remodeling enzymes holds great promise for treating soft tissue sarcomas (STS) since 1) the key oncogenic drivers in many sarcomas are translocation-derived chimeric transcription factors whose activiti... Read More

Plexin-Semaphorin: a new signaling axis in Sarcomas

Charles Keller III, MD, Children's Cancer Therapy Development Institute
Recipient of the: Race to Cure Sarcoma Research Award

Abstract: The Plexin-Semaphorin pathway is previously unexplored as a target in sarcomas but may play a central role in the progression of the soft tissue sarcoma, rhabdomyosarcoma. Rhabdomyosarcoma is the most common soft tissue sa... Read More